Loading company…
ID 405089522 · FY 2020–2024 · 5 years
ძირითად საქმიანობას წარმოადგენს ფარმაცევტული და პარაფარმაციის პროდუქტების იმპორტ-ექსპორტი და საბითუმო რეალიზაცია.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|
| Total Revenue | 2,585 | 4,190 | 6,716 | 8,402 | 12,623 | +48.7% |
| Total COGS | -950 | -1,315 | -1,933 | -2,115 | -3,314 | +36.7% |
| Gross Profit | 1,635 | 2,875 | 4,782 | 6,287 | 9,309 | +54.5% |
| Gross Margin | 63.2% | 68.6% | 71.2% | 74.8% | 73.7% | |
| Total Operating Expenses | -762 | -1,221 | -2,047 | -3,195 | -5,842 | +66.4% |
| EBITDA | 872 | 1,654 | 2,735 | 3,092 | 3,467 | +41.2% |
| EBITDA Margin | 33.8% | 39.5% | 40.7% | 36.8% | 27.5% | |
| Total D&A | -2 | -2 | -2 | -5 | -22 | +79.0% |
| EBIT / Operating Income | 870 | 1,652 | 2,733 | 3,088 | 3,445 | +41.1% |
| Total Interest Income | 0 | 0 | 0 | 0 | 16 | |
| Total Interest Expense | -0 | 0 | -2 | 0 | 0 | +468.9% |
| Total Other Income | -7 | -27 | -16 | -113 | -134 | +107.0% |
| Profit Before Tax | 863 | 1,625 | 2,715 | 2,975 | 3,327 | +40.1% |
| Total Income Tax | -72 | -58 | -138 | -319 | -317 | +45.0% |
| Net Profit / (Loss) | 791 | 1,568 | 2,577 | 2,657 | 3,013 | +39.7% |
| Net Margin | 30.6% | 37.4% | 38.4% | 31.6% | 23.9% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Ownership & directors from companyinfo.ge (public corporate registry).